Global Cancer Supportive Care Market 2017-2021

がん支持療法の世界市場2017-2021

◆タイトル:Global Cancer Supportive Care Market 2017-2021
◆商品コード:IRTNTR14883
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2017年9月21日
◆ページ数:96
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名利用)USD3,500 ⇒換算¥385,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥550,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

TechNavioが発行した当調査レポートでは、がん支持療法の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、がん支持療法の世界市場規模及び予測、地域別分析/市場規模、市場の成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

About Cancer Supportive Care
Cancer supportive care drugs are used for the treatment of adverse effects caused due to the cancer treatment such as chemotherapy-induced anemia, CINV, bone metastasis, cancer pain, and others. Various class of drugs are used as cancer supportive care drugs. Some of the major drug class that involves in cancer supportive care are antiemetic drugs, erythropoietin-stimulating agents, granulocyte-stimulating agents, analgesics, and others.

Technavio’s analysts forecast the global cancer supportive care market to grow at a CAGR of 3.38% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global cancer supportive care market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off-label drugs in cancer supportive care market.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Cancer Supportive Care Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• Amgen
• Helsinn Healthcare
• Johnson &Johnson
• Merck

[Other prominent vendors]
• F. Hoffmann-La Roche
• GlaxoSmithKline
• Heron Therapeutics
• Kyowa Hakko Kirin
• Novartis
• TESARO
• Teva Pharmaceutical Industries

[Market driver]
• Large number of side effects associated with the cancer treatment
• For a full, detailed list, view our report

[Market challenge]
• Rising popularity of targeted therapies for the treatment of cancer in developed countries
• For a full, detailed list, view our report

[Market trend]
• Advent of biosimilars in cancer-associated treatment
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?

*** You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

Table of Contents
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 06: Pipeline landscape

PART 07: Market segmentation therapeutic area
• Chemotherapy-induced anemia
• Chemotherapy-induced neutropenia
• Cancer pain
• CINV
• Others

PART 08: Geographical segmentation
• Cancer supportive care market in Americas
• Cancer supportive care market in EMEA
• Cancer supportive care market in APAC

PART 09: Decision framework

PART 10: Drivers and challenges
• Market drivers
• Market challenges

PART 11: Market trends
• Advent of biosimilars in cancer-associated treatment
• Outsourcing of biosimilars manufacturing activities

PART 12: Vendor landscape
• Competitive scenario

PART 13: Key vendor analysis
• Amgen
• Helsinn Healthcare
• Johnson & Johnson
• Merck
• Other prominent vendors

PART 14: Appendix
• List of abbreviations

[List of Exhibits]
Exhibit 01: Categories of cancers
Exhibit 02: Various modes applied for treatment of cancer
Exhibit 03: Side effects of various cancer treatments
Exhibit 04: Major drug classes used as cancer supportive agents
Exhibit 05: Global cancer supportive care market snapshot
Exhibit 06: Global cancer supportive care market 2016-2021 ($ billions)
Exhibit 07: Opportunity analysis in global cancer supportive care market
Exhibit 08: Five forces analysis
Exhibit 09: Key molecules in different stages of development
Exhibit 10: Key clinical trials
Exhibit 11: Segmentation of global cancer supportive care market by therapeutic area 2016
Exhibit 12: Segmentation of global cancer supportive care market by therapeutic area 2016 and 2021
Exhibit 13: Symptoms of anemia
Exhibit 14: Types of anemia
Exhibit 15: Global cancer supportive care market for chemotherapy-induced anemia 2016-2021 ($ billions)
Exhibit 16: Types of cancers closely associated with anemia
Exhibit 17: Commonly used ESAs
Exhibit 18: Side effects associated with the usage of ESAs
Exhibit 19: Global cancer supportive care market for chemotherapy-induced neutropenia 2016-2021 ($ billions)
Exhibit 20: Types of cancer pain
Exhibit 21: Global cancer supportive care market for cancer pain 2016-2021 ($ billions)
Exhibit 22: Global cancer supportive care market for CINV 2016-2021 ($ billions)
Exhibit 23: Major drug classes used for treatment of CINV
Exhibit 24: Analysis of global CINV drugs market
Exhibit 25: Global cancer supportive care market for others 2016-2021 ($ billions)
Exhibit 26: Some of the other side effects of cancer treatment
Exhibit 27: Effect of cancer treatment leading to oral complications
Exhibit 28: Segmentation of global cancer supportive care market by geography 2016 and 2021
Exhibit 29: Segmentation of global cancer supportive care market by geography 2016-2021 ($ billions)
Exhibit 30: Market scenario in Americas
Exhibit 31: Cancer supportive care market in Americas 2016-2021 ($ billions)
Exhibit 32: Top 10 types of cancers in US 2014 (per 100,000 people)
Exhibit 33: Cancer survivors in US: Statistics and estimations 2016 and 2026
Exhibit 34: Economic and healthcare expenditure snapshot of US 2014 and 2015 ($ billions)
Exhibit 35: Economic and healthcare snapshot of Canada 2016
Exhibit 36: New cases of cancer in Canada 2016
Exhibit 37: Market scenario in EMEA
Exhibit 38: Cancer supportive care market in EMEA 2016-2021 ($ billions)
Exhibit 39: Economic and healthcare snapshot of European region 2014
Exhibit 40: Cancer death statistics in EU 2015
Exhibit 41: Market scenario in APAC
Exhibit 42: Cancer supportive care market in APAC 2016-2021 ($ billions)
Exhibit 43: Cancer facts in China 2015
Exhibit 44: Cancer cases snapshot
Exhibit 45: Estimated investment in oncology in developed and developing countries 2017
Exhibit 46: Common side effects associated with treatment of cancer in traditional methods
Exhibit 47: General side effects of radiotherapy
Exhibit 48: Support care drugs and their effects
Exhibit 49: Demographic and economic snapshot of India and China 2014 and 2016
Exhibit 50: Factors contributing to high cost of cancer drugs
Exhibit 51: Effect of high cost of cancer drugs on cancer supportive care market
Exhibit 52: Top concerns of health insurance in US
Exhibit 53: Competitive structure analysis of global cancer supportive care market 2016
Exhibit 54: Amgen: Key highlights
Exhibit 55: Amgen: Strength assessment
Exhibit 56: Amgen: Strategy assessment
Exhibit 57: Amgen: Opportunity assessment
Exhibit 58: Helsinn Healthcare: Key highlights
Exhibit 59: Helsinn Healthcare: Strength assessment
Exhibit 60: Helsinn Healthcare: Strategy assessment
Exhibit 61: Helsinn Healthcare: Opportunity assessment
Exhibit 62: Johnson & Johnson: Key highlights
Exhibit 63: Johnson & Johnson: Strength assessment
Exhibit 64: Johnson & Johnson: Strategy assessment
Exhibit 65: Johnson & Johnson: Opportunity assessment
Exhibit 66: Merck: Key highlights
Exhibit 67: Merck: Strength assessment
Exhibit 68: Merck: Strategy assessment
Exhibit 69: Merck: Opportunity assessment



【掲載企業】

Amgen, Helsinn Healthcare, Johnson &Johnson, and Merck, F. Hoffmann-La Roche, GlaxoSmithKline, Heron Therapeutics, Kyowa Hakko Kirin, Novartis, TESARO, and Teva Pharmaceutical Industries.


【資料のキーワード】

癌支持療法

★調査レポート[がん支持療法の世界市場2017-2021] (Global Cancer Supportive Care Market 2017-2021 / IRTNTR14883)販売に関する免責事項
[がん支持療法の世界市場2017-2021] (Global Cancer Supportive Care Market 2017-2021 / IRTNTR14883)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆